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ABSTRACT 
 
The dietary isoflavone supplements are now perceived as safe and a natural alternative 
to hormone replacement therapy (HRT) and are recently being consumed by 
postmenopausal women.  However, as weak estrogens, isoflavones may have the 
potential to alter breast cancer (BC) growth and metastasis which is also more common 
in the postmenopausal age group.  In this study, we investigated the role of the main 
soy isoflavone, genistein, on the metastasis of 4T1 murine BC cells implanted in 
ovariectomized (OVX) BALB/c mice (OVX mice mimic the postmenopausal age group).  
I hypothesized that weakly estrogenic genistein will enhance BC metastasis based on 
our previous studies.  This study was conducted in two treatment groups: control group 
consisting of animals on the AIN-93G control diet and genistein group consisting of 
animals on the control diet + 750ppm genistein; which can provide physiologically 
relevant plasma concentrations to what is observed in humans consuming isoflavone-
containing diets.   
 
In this thesis, three investigations were conducted: 1) to apply bioluminescence imaging 
(BLI) techniques to monitor the tumor progression in vivo of the two dietary groups; 2) to 
determine the effect of genistein on the tumor burden of the India ink-stained lungs, one 
of the common metastatic sites; 3) to evaluate the effect of genistein supplementation 
on overall tumor colonies and tumor areas of both macro- and micro- metastases in the 
lung samples with Hematoxylin and Eosin (H and E) staining.   
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We demonstrated that 750ppm dietary genistein did not promote BC metastasis to the 
lungs in BLI compared to the control group.  No significant difference in lung tumor 
burden was observed between the two groups with India ink and H and E staining 
techniques.   
 
In conclusion, this appropriate preclinical postmenopausal animal model and the BLI 
system allow us to investigate the impact of genistein on BC metastasis under low 
plasma estradiol concentrations environment.  Results from this study suggest that 
consumption of products containing genistein in a physiologically relevant level of a soy 
diet did not show any effect on breast tumor metastasis in vivo.   
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CHAPTER I     INTRODUCTION 
 
BC is the most common type of cancer among women in the United States and 
accounts for one in four newly diagnosed female cancer cases1.  It was estimated that 
in 2009, 192,370 new cases of invasive BC would occur among American women, in 
addition to 62,280 new cases of in situ BC1.  BC is a progressive disease that begins in 
breast tissue which may then invade the surrounding tissue and later extend to other 
parts of the body (metastasis).  While precise causes of the disease have not been fully 
understood, some factors are believed to contribute to the development of BC in 
women1.  One important risk factor is the lifetime exposure of women to estrogen, which 
is thought to promote cancer growth and development.  Longer exposure of 
endogenous estrogen such as early menarche, late menopause or late first full-term 
pregnancy, is proved to be associated with higher risk of BC.  The use of exogenous 
estrogen such as oral contraceptives or HRT, especially in combination with progestin, 
has been shown to increase BC incidence as well.   
 
Since the 1960s, HRT has been used to treat menopausal symptoms resulting from 
declining hormonal levels, mainly estrogen and progesterone, during menopause.   
However, there have been concerns that long-term use of HRT may increase the risk of 
developing BC2.  As a result, women, especially those with BC, are not recommended 
to take HRT in order to avoid the risk of tumor development or recurrence.  This has 
resulted in an increased use of isoflavones as an alternative therapy to relieve 
menopausal symptoms.   
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The most abundant dietary sources of isoflavones are soybeans and soy-based food 
products.  Due to their plant-derived nature and their structural similarity with female 
hormone 17β-estradiol, isoflavones are commonly recognized as phytoestrogens which 
can bind to estrogen receptors (ERs) and exhibit estrogen-like properties.  As a result, 
in recent years, dietary supplements containing soy isoflavones have been marketed as 
natural products for postmenopausal women to treat symptoms including night sweats, 
sleep difficulties, vaginal dryness and mood changes.   
 
Furthermore, epidemiologic studies suggest that high soy intake is associated with 
lower risk of BC among Asian women 3 and early exposure to isoflavones has shown 
protective effect against later development of BC4,5.  These observations have led to the 
perception that it is safe and beneficial to consume soy isoflavones for BC patients.   
 
However, this safety assumption may not be correct.  Since isoflavones are weak 
estrogens, this makes them an effective treatment for relieving menopausal symptoms 
but also a potential risk to hormone-related diseases such as BC.  Genistein, a 
predominant isoflavone found in soy, acts as an estrogen agonist at physiological 
dosages6.  It has been demonstrated that genistein stimulates the growth of estrogen-
dependent BC cells in both laboratory and animal studies7,8,9.  In addition, genistein has 
been shown to interfere with BC treatments using tamoxifen or aromatase inhibitors in 
animals10 , 11 ,12 .  Furthermore, it has been discovered recently that genistein exerts 
estrogen-like systemic effects on the induction of BC metastasis147.  All of this evidence 
raises serious safety concerns about consumption of isoflavones by women with BC.   
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With the increasing popularity of the use of isoflavone supplements by American women 
and the safety concerns of consumption of phytoestrogens, it is important to understand 
the potential effects of isoflavones on BC, which is one of the leading diseases among 
women in the US.  The overall goal of my thesis research is to determine the role of 
dietary genistein in BC metastasis, the most important aspect affecting BC survival.  My 
overall hypothesis was that genistein will promote development of BC metastatic 
disease due to its estrogenic potential.  Following are the specific objectives and the 
hypotheses of the research presented in this thesis.   
 
Objective 1: to evaluate the effect of dietary genistein on BC progression by applying 
BLI techniques to monitor tumor progression in animal models implanted with 4T1 
murine BC cell line via tail vein injection.  My hypothesis was that genistein enhances 
BC metastasis.   
  
Objective 2: to evaluate the effect of dietary genistein on metastatic lung tumor burden 
using India ink staining techniques to aid visual counting of tumor nodules on lung 
surface.  My hypothesis was that genistein enhances metastatic tumor burden on lung 
surfaces.   
 
Objective 3: to evaluate the effect of dietary genistein on micro-metastasis in lung tissue 
with the use of H and E staining.  My hypothesis was that genistein enhances both 
macro- and micro- metastasis to the lungs.  
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CHAPTER II     BACKGROUND 
 
A. Breast Cancer 
1. Breast cancer overview 
BC is the most common form of cancer among American women, excluding skin 
cancers, accounting for nearly 1 in 4 cases of cancers diagnosed in US women1.  The 
chance of developing invasive BC at some time in a woman’s life is about 1 in 8 (12%) 
and the chance that BC will be responsible for a woman’s death is about 1 in 35 (3%).  
The American Cancer Society estimates that in 2009, approximately 192,370 new 
cases of invasive BC will be diagnosed among women, as well as an estimated 62,280 
additional cases of in situ BC (the non-invasive and the earliest form of BC) 1.  In 2009, 
approximately 40,170 will die from BC in the US1.  This makes BC the second leading 
cause of cancer death among women living in the US, exceeded only by lung cancers.   
 
Approximately 1,910 cases of BC are expected to occur among men in 2009, 
accounting for about 1% of all BCs and 440 men will die from BC1.  Although BC in men 
is rare, the incidence rate has increased annually from 1975 to 2006.  The reasons for 
the increase are still unknown.  This shows that BC occurs not only in women but 
increasingly in men.  Furthermore, men tend to delay diagnosis and therefore are more 
likely than women to be diagnosed with advanced cases of the disease, leading to 
poorer chance of survival13.   
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2. Breast cancer stages 
BC is a progressive disease that begins in the breast tissue, which is made up of glands 
for milk production (lobules) and tubes that connect lobules and carry milk to nipples 
(ducts).  The remainder of the breast is made up of fatty, connective and lymphatic 
tissue1.  Cancers originate from lobules and ducts are known as lobular carcinomas and 
ductal carcinomas respectively.  There are many different types of BC, with different 
stages (spread), aggressiveness and genetic makeup, and survival varies greatly 
depending on these factors 14 .  Most masses are benign and hence are not life-
threatening.  Some BCs are called in situ since they are confined within the lobules or 
ducts of the breast tissue.  Most cancerous breast tumors are invasive or infiltrating in 
which they invade the surrounding tissue of the breast and spread to the other parts of 
the body.   
 
Seriousness of BC is highly influenced by the stage of the disease, that is, the extent or 
spread of the cancer.  The American Joint Committee on Cancer (AJCC) has a staging 
system for BC using information of tumor size and its spread within the breast and 
nearby organs (T), lymph node involvement (N) and presence of distant metastasis (M)  
15.  A stage of 0, I, II, III or IV is assigned to describe the extent of cancer growth once 
the T, N and M are determined, with stage 0 being an early stage and stage IV being 
the most advanced stage16.  Different stages of BC are described in Table II-1.   
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Stage T, N, M Criteria Description 
0 
Carcinoma in situ (non-invasive cancer) – Lobular carcinoma in situ 
(LCIS) and Ductal carcinoma in situ (DCIS).   
I 
The tumor is no larger than 2 cm in diameter and has not spread 
beyond the breast.   
II 
The tumor is no more than 2 cm across and has spread to the axillary 
lymph nodes (the underarm lymph nodes); or the tumor is between 2 
and 5 cm and has spread to the axillary lymph nodes; or the tumor is 
larger than 5 cm and has not spread to the axillary lymph nodes.   
IIIA 
The tumor is smaller than 5 cm and has spread to the axillary lymph 
nodes; or the tumor is larger than 5 cm across and has spread to the 
axillary lymph nodes.   
IIIB 
The tumor has grown into the chest wall or the skin of the breast; or 
has spread to the lymph nodes behind the breastbone.   
IIIC 
The tumor has spread to the lymph nodes behind the breastbone and 
the axillary lymph nodes or to the lymph nodes under or above the 
collarbone.   
IV Distant metastatic cancer spread to other parts of the body.   
 
Table II-1: T, N, M staging of BC 17 
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3. Risk factors of breast cancer 
While the specific cause of BC is unclear, several factors have been known to increase 
the risk of developing the disease1.  Apart from being female18, the biggest risk factor is 
increasing age19.  The probability of developing invasive female BC in the next 10 years 
is 3.4% at the age of 60 compared to 0.44% at the age of 301.  Currently, a woman 
living in the US has a 12%, or a 1 in 8, lifetime risk of being diagnosed with BC.  Back in 
the 1970s, the lifetime risk of being diagnosed with BC was 1 in 11.  This increase in the 
likelihood of being diagnosed with BC may be due to the longer average life span of 
women.   
 
Other important risk factors include family history of the disease especially in a first-
degree relative 20 and genetic predisposition such as inherited mutations or alternations 
in the BC susceptibility genes of BRCA1 and BRCA221.  Instead of a 12% lifetime risk of 
BC, women with one of these genes have an increased risk of approximately 60%22.   
High breast tissue density (a mammographic indicator of the amount of glandular tissue 
relative to fatty tissue in the breast) 23, high bone mineral density in postmenopausal 
women24, biopsy-confirmed atypical hyperplasia and high-dose radiation to chest have 
been shown as the clinical risk factors to have a strong independent relationship with 
the development of BC.   
 
Hormonal factors are also associated with increased BC risk due to the effects of 
reproductive hormones on cancer cell proliferation and DNA damage as well as 
promotion of cancer growth.  These include early menarche (<12 years old) and late 
8 
 
menopause (>55 years old) 25, older age at first-full term pregnancy (>30 years old), 
lack of childbearing or breastfeeding 26 , postmenopausal obesity and use of oral 
contraceptives.  Recent use of HRT with combined estrogen and progestin therapy has 
shown to increase BC risk as well, with higher risk associated with longer use27,28.  One 
study found that current users of the combination of estrogen and progestin 
menopausal hormones have a relatively increased risk of developing BC of 26%29.   
 
The actions of estrogen on breast and cancer cells are believed to be mainly through 
ERs that reside in cell nucleus as transcription factors.  Upon binding of estrogen and 
other co-activators, ER modulates cellular gene transcription in target tissues30.  Briefly, 
estrogen binds to the ligand-binding domain of ER which triggers a spontaneous 
dimerization and leads to a subsequent interaction of dimer with the estrogen response 
elements (EREs) in target genes.  The ligand-receptor complex recruits co-activator 
proteins to initiate gene transcription and ultimately regulates cellular response in target 
tissues.  In the mammary gland, ER-mediated genes are associated with cell 
proliferation, differentiation and survival31 .  Through the receptor-mediated process, 
estrogen promotes proliferation and differentiation of normal breast epithelium, as well 
as initiation and progression of malignant tumors.  However, estrogens are not the only 
compounds capable of interacting with ER and eliciting a response.  Estrogen agonists 
and antagonists can also bind to ER to activate and inhibit estrogenic activities, 
respectively.   
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Obesity, as well as weight gain during adulthood, increases the chance of 
postmenopausal BC32.  A recent study showed that women who gained 55 pounds or 
more after age 18 had almost 50% greater risk of BC compared with those who 
maintained their weight.  A gain of 22 pounds or more after menopause was associated 
with an increased risk of 18%, whereas losing at least 22 pounds after menopause and 
maintaining the weight loss was associated with 57% lower BC risk 33 .  In 
postmenopausal women, circulating estrogen is primarily produced in fat tissue.  Thus, 
having more fat tissue increases estrogen levels and the likelihood of developing BC.  
Given the large percentage of women in the US who are overweight or obese, 
strategies to maintain a healthy body weight are important to reduce the risk of both 
developing and dying from BC.  As a result, there is a growing evidence of the modest 
protective effect of physical activity on BC due to its effect on body mass, hormones and 
energy balance1.   
 
In recent years, research has indicated the impact of diet and other behaviors on BC.  
These additional risk factors include a high-fat diet34, alcohol intake35 and environmental 
factors such as tobacco use and radiation36.  Recent studies have reported that even 
low to moderate alcohol consumption (3-14 drinks per week) is associated with a slight 
increase in the risk of BC by increasing estrogen and androgen levels in a dose-
dependent manner37,38.  Although radiation from mammography is a low dose, the 
cumulative effect can also cause cancer39.   
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4. Treatments of breast cancer 
To treat BC, most women will have some type of surgery which is often combined with 
other treatments such as radiation therapy and/or systemic therapy (biologic therapy, 
chemotherapy and/or hormone therapy).  BC surgery is to remove the cancer from the 
breast and to assess the stage of the disease and/or to apply partial or total 
mastectomy.  Radiotherapy is given after surgery to the region of tumor bed, to destroy 
microscopic tumors that may have escaped surgery.  Radiation can reduce the risk of 
recurrence by 50-66% when delivered in the correct dose36.   
 
Adjuvant systemic treatments (biologic therapy, chemotherapy and hormone therapy) 
can be used to destroy remaining cancer cells after surgery or to reduce tumor size 
before surgery.  Anti-cancer drugs are injected into a vein or given by mouth in which 
they travel through the bloodstream to all parts of the body.  For metastatic BC, since 
the removal of all cancer cells by surgery is not possible, systemic therapies are the 
main treatment approaches.   
 
One of the biologic therapies is the use of herceptin (trastuzumab), which is a 
monoclonal antibody that directly targets the growth-promoting HER2/neu protein that is 
overproduced in approximately 15% to 30% of breast tumors and offers survival benefit 
for some women with metastatic BC40 .  Trastuzumab, however, is expensive, and 
approximately 2% of patients suffer significant heart damage from this treatment.   
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Research has established that, in most cases, combinations of drugs are more effective 
than just one drug alone for BC treatment when applying chemotherapy41.  It is most 
effective with full dose and completion of the drug cycle in a timely manner.  These 
drugs may also be used to shrink cancer that has metastasized.   
 
BC is commonly divided into two subtypes based on the presence of ERs in tumor, 
estrogen-receptor-positive (ER+) cancer and estrogen-receptor-negative (ER-) cancer.  
According to National Cancer Institute, approximately two thirds of BC cases are ER+.  
The last systemic therapy is hormone therapy, which can be given to women with ER+ 
BC to block the effects of estrogen.  It usually involves the use of selective estrogen 
receptor modulators (SERMs) or aromatase inhibitors (AIs) 42.  Both classes of drugs 
treat BC by blocking the actions of estrogen on tumor cells, but the effect comes 
through two different mechanisms.  SERMs, such as tamoxifen, act as estrogen 
antagonists by competing with estrogen for ER binding43.  Tamoxifen has been used for 
more than 30 years as a treatment for some BCs and it is proved effective in both pre-
menopausal and postmenopausal patients with estrogen-dependent BCs.  However, 
concerns regarding tamoxifen-associated side effects, including endocrine resistance 
and endometrial cancer44, have lead to a reduction in its usage.  AIs such as letrozole, 
anastrozole and exemestane, work by inhibiting the peripheral synthesis of estrogen by 
the enzyme aromatase which converts androgens to estrogens45.  AIs are generally not 
used to treat breast cancer in pre-menopausal women since most of the circulating 
estrogen is produced by the ovaries, not by conversion of androgens to estrogens, 
blocking the enzyme aromatase does not significantly decrease the production of 
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estrogen and hence may not be effective in breast cancer treatment.  While in 
postmenopausal women, AIs have proven to be more effective in preventing cancer 
recurrence with early-stage BC and have shown improved survival and fewer side 
effects than those associated with tamoxifen46 .  However, because AIs completely 
deplete postmenopausal woman of estrogen, they can cause osteoporosis, bone 
fractures and other musculoskeletal symptoms.   
 
BC treatments can result in a variety of short-term and long-term side effects that affect 
quality of life, including psychological distress, hormonal symptoms and fatigue.   
 
5. Breast cancer metastasis 
BC causes more than 40,000 deaths in women each year47.  The majority of these 
deaths are caused by metastasis at distant organs rather than primary cancer in 
mammary gland.  About 6% of BC patients are in stage IV of distant metastasis at the 
time of disease diagnosis and up to 30% of patients diagnosed in earlier stages develop 
distant metastasis eventually48.  Distant metastasis is often associated with increased 
mortality.  In the US, a 5-year relative survival rate for localized BC is 98% and for 
regionally spread cancer is 84% but for metastatic BC is only 27%1.   
 
In recent years, some important advances have been made in understanding the 
molecular mechanisms underlying BC progression and metastasis.  A series of cellular 
events are required for the metastatic process (Figure II-1) 49.  First, new blood supply 
needs to form around primary tumor to provide an escape route for cancer cells.  This 
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process is called angiogenesis.  Through these newly developed blood vessels, cancer 
cells invade into the circulatory system.  Some cells may also enter the circulation 
indirectly through the lymphatic system.  A small part of circulating cancer cells survive 
in the bloodstream and then extravasate into distal organs, colonize and grow into a 
metastatic lesion with or without a period of latency 50.  When cancer cells spread and 
form a new tumor in a different organ, the new tumor is termed as a metastatic tumor.  
The cells in the metastatic tumor come from the original tumor.  This means, if BC 
spreads to the lungs, the metastatic tumor in the lungs is made up of cancerous breast 
cells.  When viewed under a microscope, metastatic BC cells generally look the same 
as cancer cells in the breast.   
 
 
 
 
Figure II-1: Cellular events in a metastatic process 51 
 
Whether metastases develop depends on the complex interaction of many tumor cell 
factors, including the type of cancer, the degree of differentiation of the tumor cells, the 
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location and how long the cancer has been present, the lymph node involvement, the 
absence of hormone receptor and vascular invasion 52 as well as other incompletely 
understood factors.  The patterns of metastasis are also linked to hormone receptor 
status.  ER+ cancer tends to metastasize to bone and reproductive organs, while ER- 
tumors favor viscera such as lungs53.  Cancer cells can spread to almost any region of 
the body.  The most common sites for BC metastasis are bone, lung, liver and brain54.   
Metastases may occur at a single organ but more likely develop at multiple locations.  
The two most popular sites for the metastasis of BC cells are in bone and the lungs, 
which can be found in approximately 70% of patients at the time of death55.   
 
When cancer has metastasized, it may be treated with chemotherapy, radiation therapy, 
biological therapy, hormone therapy, surgery, cryosurgery or a combination of these. 
The choice of treatment generally depends on the type of primary cancer, the size and 
location of the metastasis, also the age and general health of the patient.  Currently, 
metastatic cancer is considered incurable.  Treatments, although relatively toxic, mainly 
focus on alleviating symptoms and improving quality of life of patients.  Systemic 
adjuvant therapies may involve chemotherapy, tamoxifen or AIs for ER+ cancer, and 
trastuzumab for HER2/neu positive cancer.  Bevacizumab, an antibody targeting VEGF, 
may be used for metastasis treatment due to its inhibitory effect on angiogenesis56.   
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B. Isoflavones 
1. Isoflavone overview 
Phytoestrogens are a group of plant-derived compounds that have a similar chemical 
structure with female hormone 17β-estradiol.  Major phytoestrogens include isoflavones, 
lignans, coumestans and stilbenes, with the last two classes being less abundant in the 
diet.  Isoflavones are the most common form of phytoestrogens.  The basic structural 
feature of isoflavone compounds is shown in Figure II-2.  The flavone nucleus is 
composed of two benzene rings linked through a heterocyclic pyrane ring57.   
 
 
 
Figure II-2: Structures of major soy isoflavones, genistein and estradiol 
 
Due to this structural similarity, isoflavones have the ability to bind to ERs 58  and 
therefore act as estrogen agonists to exert weak estrogenic effects59.  The estrogenic 
activity of isoflavones is generally 102-105 weaker than estradiol.  Genistein, one type of 
isoflavone, binds to ERs with an affinity approximately 100-fold less than that of 
estradiol60.  Nevertheless, plasma isoflavone concentration can be 102-103 higher than 
endogenous estradiol following a soy-rich diet61.  Adlercreutz et al. 62 have found that 
the plasma level of genistein in people having a soy rich diet was 1-5 μM after 
Major soy isoflavones Estradiol Genistein 
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metabolism and excretion.  A recent report from India also revealed an adequate 
circulating level of genistein after a single dose of soy extract63.   
 
Isoflavones are present in a variety of plants such as legumes and clovers, but the most 
abundant dietary sources of isoflavones are soybeans and soy-based food products64.   
Three main isoflavones are genistein, daidzein and glycitein, which account for 
approximately 50-55%, 40-45% and 5-10% of the total isoflavones content in soy 
respectively65.  Naturally occurring isoflavones are in their glycoside inactive forms as 
genistin, daidzin and glycitin.  Upon consumption, the conjugated compounds are 
metabolized by intestinal bacteria to produce active aglycone form of isoflavones66.   
 
The consumption of isoflavones varies between Eastern and Western countries 67 .   
Among Asian populations such as Chinese and Japanese, between 25-50 mg of 
isoflavones are typically consumed daily.  However, the intake of isoflavones in the US 
and Europe is significantly lower, with the average intake being less than 1 mg per day.  
In addition, the forms of isoflavones taken by the two cultures are also different.  It is 
more common in Asian diets to include traditional non-fermented soy foods (tofu, 
soybeans and soy milk), fermented soy foods (miso and natto) or other soy products 
(fried, dried and pressed soy products).  In contrast, in Western populations, Asian soy 
foods are rarely consumed but isoflavones are attained mainly in pure or enriched forms 
of soy protein isolates or dietary supplements together with small quantities from 
legumes, sprouts and some other vegetables.  It has been shown that 10 mg of 
isoflavones everyday, obtained in a standard serving of tofu, may have lasting beneficial 
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effects against BC development in Asian women68.  In parallel, relatively high levels of 
soy isoflavones have been found in serum, urine and prostatic fluid of Asian men who 
consume a soy-rich diet which possibly contribute in lowering the incidence of prostate 
cancer69.  Hence, it is believed that the decreased risk of localized prostate cancer was 
also associated with soy product and isoflavone consumption70.   
 
It is believed that due to the high daily intake of soy isoflavones as an important dietary 
component for centuries, there are lower incidences of certain chronic diseases such as 
heart disease and cancer in Asian populations.  In particular, epidemiologic studies 
have associated high soy intake with many health benefits, such as lowering incidence 
of cancers especially breast, prostate and colon cancers, protection from cardiovascular 
diseases71, prevention of osteoporosis and attenuation of menopausal symptoms72.   
Soybeans contain numerous biologically active compounds that may be important in BC.  
Although it is not clear which component of soy is the most responsible for its overall 
effects, isoflavones are believed to be important for these health benefits73,74.   
 
Laboratory research backed by epidemiological studies emancipating from the last few 
decades have provided convincing evidence that isoflavones in soy-rich foods 
contribute to relatively lower rates of BCs in Asian countries such as China and Japan 
than in Western populations (Figure II-3).  On average, 1 in 8 women in the US develop 
BC compared to 1 in 30 women in Japan.  Furthermore, the incidence of BC in migrant 
Japanese women to the US increases in the first and second generations of offspring 
after settlement in the US75.  Epidemiologic studies attribute the protective effect against 
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BC in Asian women to lifestyle, environmental and dietary factors, especially the high 
consumption of soy-contained foods76.  Increased soy food intake was associated with 
reduced risk of BC among pre-menopausal women77, postmenopausal women 78 and 
also BC survivors 79 .  In addition, protection against BC can be lost with a few 
generations after Asian immigrants are exposed to Western lifestyles 80 , 81 , 82 .  This 
observation further suggests that lifestyle and eating habit, in particular soy and 
vegetable intake, may play an important role in BC risk.   
 
 
 
Figure II-3: Female BC incidence and mortality rates, 2002-2006 1 
 
Based on epidemiological findings of the relationship between soy and BC, numerous 
studies have been conducted to investigate the role of soy isoflavones in cancer 
Caucasian 
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development.  Clinical and preclinical laboratory animal and in vitro studies have 
demonstrated the hormonal activity of dietary isoflavones.  It has been proposed that 
isoflavones, due to their estrogenic activities, are responsible for the chemoprotective 
effect of soy against BC83.   
 
2. Genistein and breast cancer 
Isoflavone components found within dietary supplements are biochanin A, genistin, 
genistein, formononetin, daidzin and daidzein84.  In these products, genistein (4,5,7-
trihydroxyisoflavone) is typically the isoflavone in the highest concentration85.  Because 
of its structural similarity to 17β-estradiol, genistein has shown to compete with 17β-
estradiol in ER binding assays.  Kuiper et al. 86 reported that genistein binds to both ERs, 
with higher affinity to ER-β.  The binding affinity of genistein for ER-α was 4%, and for 
ER-β was 87%, compared to estradiol.  Thus, it is hypothesized that, by its affinity and 
competition with estrogen in interacting with ERs, genistein blocks the binding of more 
potent estrogen and also affects estrogen metabolism, thereby exerting a potential 
favorable role in the prevention of hormone related cancers.   
 
Genistein, the predominant isoflavone found in plant food such as soybean which 
comprises a significant portion of Asian diet, has shown to inhibit carcinogenesis in 
animal models, via modulation of genes that are related to the control of cell cycle and 
apoptosis.  Genistein inhibits activation of NF-κB and Akt signaling pathways, both of 
which are known to maintain a homeostatic balance between cell survival and 
apoptosis33.  Moreover, genistein antagonizes estrogen- and androgen-mediated 
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signaling pathways in the processes of carcinogenesis.  Furthermore, genistein has 
been found to have antioxidant properties and shown to be a potent inhibitor of 
angiogenesis and metastasis.  Taken together, both in vitro and in vivo studies have 
clearly shown that genistein is a promising agent for cancer chemoprevention and an 
adjunct to cancer therapy.   
 
It has been reported that early exposure to reproductive hormones reduces the 
incidence of BC in women 87 and the preventive effect on BC following early exposure to 
isoflavones in childhood or adolescence has been observed in some epidemiologic 
studies4,5.  Lamartiniere et al. demonstrated that pre-pubertal exposure to genistein 
before administration of the carcinogen DMBA (dimethylbenzanethrene) was protective 
against mammary cancer in rats88,89.  This may due to the stimulatory effect of genistein 
on mammary gland cell maturation90.  Nagasawa et al. suggest that genistein acts as an 
estrogen agonist to enhance mammary gland differentiation and the differentiated cells 
undergo less proliferation and therefore are less likely to progress through cancer 
process 91 and this may be the mechanism responsible for the chemopreventive effects 
of genistein in the rat DMBA mammary carcinogenesis model92.   
 
However, not all studies have reported such protection against tumor development.  
Approximately two thirds of BCs are ER+ and isoflavones may adversely affect these 
tumors by exerting estrogenic and proliferation-inducing effects.  Additionally, it is 
observed that the timing of exposure, the dosage applied and the form administrated 
are important issues that determine the outcome of isoflavone consumption on BC.   
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The protective effect of genistein against later development of BC may not apply to 
existing mammary tumors.  Both laboratory and animal studies have shown that 
genistein acts as an estrogen agonist to stimulate the growth of ER+ BC cells93.  In vitro, 
it has been demonstrated that genistein enhanced the growth of estrogen-dependent 
human BC cells at concentration as low as 10 nM and achieved proliferative effects 
similar to those of 1 nM estradiol with concentration of 100 nM.  Expression of the 
estrogen-responsive gene pS2 was also induced in ER+ cell lines in response to 
treatment with a concentration of genistein as low as 1 µM65.  In vivo, Ju et al. showed 
that physiological dosages of genistein stimulated MCF-7 tumor growth in athymic mice 
in a dose-dependent manner94.  Thus, whether genistein acts as a chemopreventive 
agent or as a stimulatory agent to tumor growth is likely dependent on the timing of 
genistein administration.  Furthermore, several animal studies have demonstrated that 
dietary genistein can interfere with BC treatments by negating or overwhelming the 
inhibitory effects of anti-estrogen tamoxifen or aromatase inhibitor letrozole10,11,12, which 
further confirmed that genistein acts estrogenically via binding with the ERs.   
 
Dosage of genistein used may also pose different effects on BC.  High concentrations of 
genistein (>20 µM) inhibit the growth of estrogen-dependent human BC cells in vitro95.  
This anti-proliferative effect of genistein may be through its blocking effect of the cell 
cycle at G2-M phase and this inhibits tyrosine phosphorylation
96,97,98.  However, it is 
unlikely that the concentration required to inhibit MCF-7 cell growth can be achieved in 
vivo and hence such high concentrations in blood are not likely to be obtained from 
dietary exposure of genistein in humans as well99.  Even if the conjugated form is 
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biologically active, these levels are below the high concentrations required in vitro to 
produce a dose-dependent inhibition in tumor cell growth.  While on the other hand, the 
low concentrations (0.1 to 1 µM) are easily achieved from typical consumption of dietary 
isoflavones among American women100.  Unfortunately, these physiologically relevant 
levels appear to be stimulatory to tumor development as documented previously.   
 
There is some evidence suggesting that the effect of isoflavones on BC may also 
depend on the hormonal status of a woman.   Case-control studies often found that soy 
is more protective against BC in pre-menopausal women than in postmenopausal 
women101.  Animal studies conducted on intact animals found that soy protein isolate 
containing genistein had no effect on mammary tumor growth102, while studies using 
OVX mice observed tumor-stimulating effects from dietary genistein66.  This data 
suggests that in the presence of higher circulating estradiol levels, genistein may have 
insignificant impact on BC growth and development.  However, when endogenous 
estradiol concentrations are low, genistein may be capable of stimulating tumor growth.  
This is an important issue because majority of BC cases are diagnosed in 
postmenopausal women whose endogenous estrogen levels are naturally very low and 
their body cells are hypersensitive to exogenous estrogens and estrogen agonists such 
as genistein.  Consequentially, the estrogenic activity of these weak estrogens, 
isoflavones, may be more significant in postmenopausal women.   
 
In addition, the sources of isoflavones may also have an impact on BC.  In Asian 
countries, most isoflavones come from traditional soy diets, such as tofu and miso.  
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However, the intake of soy-based food remains low in the US, while consuming isolated 
soy isoflavones in pure form as in supplements or food products such as soy protein 
isolates are more popular approaches to increase isoflavone intake103.  An animal study 
conducted by Allred et al. demonstrated that soy flour did not stimulate MCF-7 
mammary tumors, while isoflavone extracts and pure forms did promote tumor growth104.  
This result suggests that consuming less-processed soy foods instead of purified forms 
may be safer to women with BC.   
 
There is still no conclusive clinical trial available to confirm the effect of isoflavones in 
humans.  Some studies showed that exposure to various doses of soy isoflavones did 
not reduce mammographic density in pre-menopausal 105 and postmenopausal women 
106 while some studies found that soy supplementation stimulated mammary gland cell 
proliferation in healthy women107,108.  Petrakis et al. demonstrated that consumption of 
soy protein isolate had stimulatory effects on breast tissue of pre-menopausal women109.   
These results suggest that soy isoflavones might increase BC risk in humans and hence 
bring serious concerns on the safety of consumption by women with BC.   
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C. Imaging techniques for cancer research 
Biomedical research is often limited by the difficulty of gathering data from animals in a 
real-time longitudinal manner.  The advances of molecular imaging technology have 
expanded the limits of animal research and allow cancer biologists to collect 
physiological and pathological information at multiple time points without sacrificing the 
animals.  Using this approach, animals can act as their own control, which will produce 
more accurate and valuable information than that from various samples.  As a result, 
non-invasive in vivo imaging in animal research has a clear advantage when monitoring 
a biological progressive process, such as cancer metastasis110.  The main techniques 
used in animal research include Positron Emission Tomography (PET), Computed 
Tomography (CT), Magnetic Resonance Imaging (MRI) and optical imaging using 
fluorescence or bioluminescence111.   
 
In our study, one of the optical imaging techniques was employed.  To create images in 
optical imaging, an agent that can be detected through fluorescence or luminescence is 
administrated to the animals and a highly sensitive charge coupled device (CCD) 
camera is required to detect the light from visible to near-infrared range.   
 
In fluorescence imaging (FLI), a colored protein, such as green fluorescent protein 
(GFP), is transfected into the cells so that they can be visualized from inside the body.  
This optical technique produces excellent images with structures near the surface but is 
limited to organs deep in the body112.   
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In BLI, which was used in our experiment to follow BC progression, the light emitted is 
originated from a substrate-enzyme reaction113.  This can be done by tagging the cells 
with luciferase photon protein isolated from fireflies and prior to imaging, delivered to the 
animals with the firefly luciferin substrate in order to carry out the reaction which will 
emit light.   
 
There are many advantages of employing BLI for animal research: 1) the use of 
luciferase as optical indicators allows detection of low levels of light signal because of 
its low noise background in live mammalian cells and tissues114 ; 2) the substrate-
enzyme reaction allows expression of luciferase only in the labeled cells and tissues 
which increases the specificity of the imaging.  3) BLI is a small and convenient unit that 
can complete the measurement in a short period of time, which makes it practical to 
image approximately 60 animals in one day.  All of these advantages make BLI an 
attractive non-invasive imaging modality for animal and cancer research.   
 
However, on the other hand, there are some limitations of BLI in BC metastasis 
research: 1) optical imaging is based on 2D image and hence results in poor spatial 
resolution115; 2) light emitted from the enzymatic reaction can be attenuated by different 
organs and tissues, which is why metastasis in lung areas is always more easily 
detected than in liver areas in the imaging116; 3) it is difficult to distinguish anatomic 
structures in the images because of the overlapping of light emitted from adjacent 
areas117.  All of these disadvantages make BLI a semi-quantitative method for cancer 
metastasis detection.   
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CHAPTER III    METHODS 
 
A. Materials 
Murine 4T1 BC cells, labeled with firefly luciferase (FL), were kindly provided by Dr. 
David Piwnica-Worms from Washington University (St. Louis, MO).  Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 1% glutamine and Heat 
Inactivated Fetal Bovine Serum (HI-FBS) were purchased from the Cell Media Facility of 
the school of Chemistry Sciences, at the University of Illinois at Urbana-Champaign 
(UIUC).  Penicillin/streptomycin and trypsin/EDTA were purchased from Invitrogen 
(Carlsbad, CA).  MatrigelTX matrix was purchased from BD Biosciences (San Jose, CA).  
Hanks balanced salt solution was purchased from Sigma-Aldrich (St Louis, MO).  
Laboratory animal diets were purchased from Research Diets (Brunswick, NJ).  GEN 
was purchased from Indofine Chemical Company (Hillsborough, NJ).  D-luciferin 
potassium salt was purchased from Regis Technologies (Morton Grove, IL).  India ink 
was purchased from Sanford (Bellwood, IL).   
 
B. Animals and diets 
Thirty three 4-to-6-week old female OVX BALB/c mice were purchased from Charles 
River Laboratories (Wilmington, MA).  Mice were ovariectomized at 21-days of age by 
the vendor and were allowed 1 week to recover after delivery.  The animals were single 
caged in a controlled environment and were maintained under the standard light-dark 
cycle with artificial light (12-hour light and 12-hour dark) and were allowed unrestricted 
access to water and modified AIN-93G diet.  All the housing and animal care was 
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carried out under approved animal study protocols by the Institutional Animal Care and 
Uses Committee (IACUC) of UIUC.  During the study, the mice body weights were 
monitored and recorded weekly.  Uterine wet weights were measured after the mice 
were sacrificed at the end of the study.   
 
American Institute of Nutrition-93 Growth (AIN-93G) semi-purified diet was selected as 
a base diet for control mice as it has been established to meet all the nutritional 
requirements of mice118.  All the mice were fed AIN-93G diet throughout the study.  One 
concern for the use of a commercial diet is the presence of phytoestrogens from plant 
sources such as soybean meal.  Protein in the AIN-93G diet is derived from casein only 
and soybean oil was substituted with corn oil as a sole fat source; thus, the potential 
interference of phytoestrogens in soy-based protein and fat supplements is eliminated.   
 
C. 4T1 cell culture 
The murine metastatic mammary carcinoma 4T1 cells are a transplantable tumor cell 
line119,120.  The 4T1-FL cells were maintained in DMEM supplemented with 10% HI-FBS, 
1% glutamine, 100 U/mL penicillin, 100 g/mL streptomycin and 0.1% fungizone and 
incubated at 37°C with 5% CO2 and 95% humidified air as a monolayer culture in 100 
mm x 20 mm tissue culture polystyrene plates.  Cells were harvested at 70-80% 
confluence by washing two times with 1X PBS followed by trypsinization with trypsin-
EDTA.  Cells were counted using a hemocytometer (Fisher Scientific, Pittsburgh, PA) 
and diluted in Hanks balanced salt solution to a concentration of ~5000 cells/100 µL 
before tail vein injection to the mice.   
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D. Tail vein injection of 4T1 cells 
In this study, tail vein (TV) metastasis model was used.  To make the mouse tail vein 
easier to locate for injection, the mice were placed in a mouse restrainer and the lateral 
tail veins were dilated by warming the tails in 42°C water for 3 min.  5000 4T1 cells in 
100 L Hanks balanced salt solution were injected intravenously into the lateral tail vein 
of each mouse.  Dietary treatments were started on the same day.  Mice were randomly 
divided into two groups in which they were fed with either AIN-93G as the control diet or 
AIN-93G plus 750 parts per million (ppm) genistein.  Mice were also weighed once a 
week to monitor their weight difference in the two diets.  To detect and monitor tumor 
metastasis, BLI was conducted on all of the mice routinely throughout the study (2 times 
a week) and the final imaging was performed prior to sacrifice.  The study lasted 3 
weeks after the tail vein injection.  A thorough necropsy was conducted to verify 
metastasis at the time of sacrificing the mice.  The lungs from all mice were infused with 
India ink to evaluate lung metastasis.  All the protocols used in these experiments were 
approved by the IACUC at UIUC.   
 
E. Bioluminescence imaging 
BLI was carried out using a custom built imaging system assembled by Stanford 
Photonics (Palo Alto, CA) which included a photon-tight box, bright field illumination, 
warming plate and a dual micro-channel plate intensified charge coupled device (CCD) 
camera (Mega 10-Z with cathode cooling).  Mice were injected intraperitoneally with 15 
mg/mL D-luciferin solution in PBS was freshly made before each time of imaging.  The 
amount of D-luciferin for each mouse was determined by body weight according to the 
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equation:  Dosage (µL) = 10 x body weight (g).  Three minutes after administration of D-
luciferin, which is the time for optimal luciferase-luciferin activity, the mice were 
anesthetized using isoflurane/O2 gas from a vaporizer and placed face-up in a height-
adjustable tray in the imaging system for a whole body scan.  General anesthesia was 
maintained through an inlet tube during the scanning process.  Photon emission was 
accumulated for a 3-minute period using the imaging software Piper Control (Stanford 
Photonics, Palo Alto, CA) under movie mode which provided continuous recording of 
discrete 66 imaging frames and allowed analyzing and processing images at any time 
point during the 3 minutes.  Bioluminescence was visualized as a pseudocolor scale: 
blue, the lowest photon flux; green, the highest photon flux which indicates that the 
imaging summation memory within Piper Control has reached full 16 depth.  Acquired 
images were post-processed using the software ImageJ (NIH, Bethesda, MD) and 
Photoshop Elements (Adobe, San Jose, CA) software to combine background image 
(mouse body) with imaging data (tumor).  Metastasis was semi-quantified using ImageJ 
based on two parameters, the bioluminescent area and the integrated density of the 
metastases.  The images were set as 8-bit and the threshold for measurement was set 
at 50 (maximum 256).   
 
F. Analysis of uterine wet weights 
During necropsy, the mice were sacrificed and the uteri were removed and all 
connective and fat tissues were cleaned for assessment of wet weights.  The uterine 
wet weight for each animal was measured and recorded.   
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G. India ink staining of animal lungs 
The animal was placed on its back after being euthanized by CO2.  The rib cage was 
cut open to expose the lungs and an incision was made on the neck to expose its 
trachea carefully.  Two mL of India ink solution (85% India ink / 15% dd H2O) was slowly 
infused into the lungs through the trachea by a 25-gauge needle.  The infused lung 
samples were kept in Fekete’s solution (900mL 70% ethanol / 90mL 37% formaldehyde 
/ 15mL 91% acetic acid) for destaining.  The tumor nodules do not absorb India ink, 
which results in the normal lung tissue staining black while the tumor nodules remain 
white.  White tumor nodules were counted blindly by 3 individuals and the numbers 
were recorded and averaged as the tumor count on the lungs for each of the animals.  
This is a well accepted method for determining tumor load on the lungs.  Lung samples 
were then further processed for the H and E staining to look for micro-metastases inside 
the lung tissue.   
 
H. Hematoxylin and Eosin staining of lung samples 
After tumor counting of the India ink-infused lungs, samples were dissected carefully.  
Two sections were vertically cut from the right lobe and another two sections were cut 
from the lowest lobe of the left side of the lungs.  Matching locations were chosen for all 
the lung samples.  To prepare the staining sections, the 4 lung sections were embedded 
in a paraffin block and the block was sliced into 5 m sections and 3 sections per lung 
sample were randomly chosen to be mounted on the microscope slides.  The slides 
were then stained by the conventional H and E staining and observed under the 
AxioSkop 40 microscope (Carl Zeiss, Thornwood, NY) for both macro- and micro-
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metastasis.  The pictures of the regions of interest (ROI) were taken and transferred to 
a computer screen using Axio Cam HRc (Carl Zeiss, Thornwood, NY).  Metastasis was 
quantified by counting the tumor colonies in the lung tissue per section and measuring 
tumor areas using AxioVision AC software (Carl Zeiss, Thornwood, NY).  Tumor area 
data are shown as parts per thousand of the tumor areas in the whole lung tissue per 
section.  All slides were measured in a blind fashion without knowledge of the treatment 
groups.   
 
I. Statistical analysis 
Nonparametric statistical tests were performed for the independent and not normally 
distributed data from BLI, India ink staining and H and E staining in the experiment.  All 
results were analyzed with the independent two-group Wilcoxon Rank Sum Test using 
the SAS program (SAS, Cary, NC).  Error bars on all graphs are representative of the 
standard error of the mean.   
 32 
 
CHAPTER IV    RESULTS 
 
A. Effect of genistein on animal weight 
Animal weights were recorded once a week throughout the study starting from week 0 
of tail vein cell injection until week 4 before the sacrifice of the mice.  Figure IV-1 shows 
that body weights of the mice were slightly increasing throughout the study in both 
groups but there was no significant difference between the two diet groups on each day 
of measurement.  It indicated that genistein diet did not affect the growth of the animals 
with metastatic BC during the experimental period.   
 
B. Effect of genistein on uterine wet weight 
Uterotrophic effects are directly affected by an estrogen receptor-mediated mechanism, 
especially by ER-α agonists and antagonists121.  Internal organs including the uterus 
were collected upon sacrifice of the mice on Day 21.  The uterus was removed and all 
of the connective and fat tissues were cleaned during necropsy to minimize inaccurate 
measurement.  Then the uterine wet weight was measured by an accurate balance in 
milligrams (mg).  The average uterine wet weights of the control group and genistein 
group were 9.89 ± 1.0 mg and 9.86 ± 0.9 mg respectively, as shown in Figure IV-2.   
The genistein diet did not affect the uterine wet weight significantly compared to the 
control diet, proving that, although genistein has a similar structure to estrogen, it does 
not have as great an estrogenic effect on the uterine weight.   
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C. Bioluminescence imaging analysis 
Twice-a-week BLI provided longitudinal monitoring of the metastasis progression.  This 
technique is non-invasive, convenient and time-saving.  It involves an enzymatic 
reaction between luciferase which is engineered into the tumor cells and the substrate 
luciferin, which is usually administrated intraperitoneally and distributed rapidly through 
the whole body, passing all blood-tissue barriers, including brain and placenta117.  Then 
the light emitted from the reaction is captured by a CCD camera.  With the 
bioluminescence images, three parameters can be analyzed and used to reflect the 
metastatic tumor spread and severity.  First, the metastasis occurrence rate was 
determined.  Then metastatic tumor area and integrated density of the images were 
measured.  All bioluminescence images were measured with the same threshold.   
 
1. Metastasis occurrence rate 
A mouse was counted as having metastasis when there was fluorescence light captured 
in the image regardless of the light intensity and the size of the metastases.  The 
metastasis occurrence rate was expressed as the number of metastasis occurrences 
over sample size and the percentages were also calculated.  BLI was carried out on 
Day 2, 6, 9, 13, 16 and 21 for both groups.  On Day 21, one mouse was found dead in 
the genistein group.   
 
The data for the number of mice showing metastasis is summarized in Table IV-1.  The 
metastasis progression showed a gradually increasing growth pattern.  There was no 
visual metastasis on BLI, even with increased contrast, until Day 9 of the study.  
 34 
 
However, the metastasis appeared and increased as the experiment proceeded for both 
groups.  From Day 9 to Day 13, the animals showing metastasis increased from ~20% 
to ~80% in both groups.  Also, once the metastasis was detected by BLI, it kept 
spreading and the light emitted from the enzymatic reaction captured by the camera 
became increasingly stronger (Figure IV-3).  After that, the rate remained high for both 
groups but genistein group showed decreased rate towards the end of the study.  On 
the last imaging day (Day 21), control and genistein groups had ~88% and ~71% of 
metastasis occurrence rate, respectively.   
 
Throughout the study, the BLI results indicated that genistein treatment resulted in 
decreased metastasis occurrence rate compared to that of the control group.  However 
the difference on imaging was not significant indicating that the dietary genistein did not 
alter the development of metastasis to the lungs.   
 
From imaging pictures, it was observed that metastasis occurred not only in the lungs 
but also in other organs including the lymph node, abdomen, leg and pelvis as shown in 
Figure IV-4.   
 
2. Area and integrated density of metastases 
After counting the number of mice showing metastasis, we measured the area and 
integrated density of the metastatic tumors using ImageJ at a setting of 8-bit and 
threshold 50.  This is only a semi-quantitative measurement giving a general idea of the 
BC metastasis.  The images from BLI were analyzed from Day 2 to Day 21.  Results of 
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the BLI area and integrated density on each day of imaging with the two groups of mice 
are summarized in Figure IV-5 and Figure IV-6, respectively.  Both parameters showed 
similar trends.  There is no metastasis observed for the first 2 days of imaging.  From 
Day 9 onwards, the metastasis progression was gradually increasing until it reached the 
highest level on the day before mice sacrifice.  Same as the result of the metastasis 
occurrence rate above, the genistein group showed less metastasis in each day of 
measurement with metastasis progressing more slowly throughout the experiment 
compared to the control group.  However, with the use of the Wilcoxon Rank Sum Test 
for statistics, there is no significant difference between the two groups, in terms of the 
measured area and integrated density of the light captured from the BLI.   
 
D. India ink staining analysis 
India ink staining was conducted to count visible tumor nodules on the surface of lung 
samples.  Compared to the original lung sample, the use of India ink infusion provides 
an easier visual observation of tumors on the lung surface as demonstrated in Figure 
IV-7.  On average, 1.95 ± 0.49 white tumor nodules were counted in the genistein group, 
compared to 2.15 ± 0.57 of the control group (Figure IV-8).  There is no significant 
difference in the number of tumors on the lung surface between the two groups.  
Genistein group did not show any effect on the metastatic tumor burden.   
 
E. Hematoxylin and Eosin staining analysis 
H and E staining was carried out to quantify micro-metastasis inside the lungs in order 
to evaluate the severity of tumor burden.  Two parameters were analyzed for the H and 
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E stained lung tissues, counting of both the macro- and micro-tumor colonies and 
measuring of the tumor area of the observed metastases.   
 
1. Tumor colonies of lung samples 
After India ink staining, the normal lung cells were black in color while the dense tumor 
cells appeared in reddish purple color as a consequent of the H and E staining.  In this 
way, we could easily distinguish normal and tumor cells under the microscope.  H and E 
can also detect micro-metastasis which cannot be observed with India ink staining.  We 
observed large tumor areas in the lung tissue from mice with their India ink-infused 
lungs also showing white tumor nodules on the surface.  In addition to the macro-
metastasis, we counted small tumor areas (micro-metastasis) as well.  The 
representative images of H and E stained macro-metastasis and micro-metastasis are 
shown in Figure IV-9 and Figure IV-10 respectively.  Both macro- and micro metastasis 
were added together and expressed as the total tumor counted in each of the lung 
samples and used to compare the effects of the two diet groups.  On average, 4.20 ± 
0.99 tumor colonies were observed in the genistein animals while 4.31 ± 1.14 tumor 
colonies were counted in the control animals.  This trend of having less metastatic lung 
tumors observed in the genistein group was consistent with both the results of BLI and 
that of India ink.  However, again, the data did not show any significant difference 
between the two groups.  The results of tumor count after H and E staining is shown in 
Figure IV-11.   
 
 
 37 
 
2. Tumor areas of lung samples 
Pictures of the tumor colonies were taken with the tumor cells on the background of the 
India ink-stained normal cells.  Then the area of all the tumor colonies in a lung sample 
was measured.  To compare the effect of the two diets on metastasis, the ratio of the 
measured tumor area to the whole lung area was used.  In Figure IV-12, which displays 
the ratios of each individual animal and the mean ratio for both groups, it shows that the 
control group had relatively lower tumor area/lung area ratios with its average tumor 
area ratio smaller than that of the genistein group.  Although this result was opposite to 
the previous experimental approaches, again the increase in the genistein group was 
not significant compared to the control group.   
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Figure IV-1: Animal weight throughout experimental period 
 
Measurement was carried out once a week.  Results were expressed as mean ± 
standard error.  Control group with n = 16 while genistein group with n = 14/15.  
Animals’ weights increased slightly for both groups throughout the duration of the study 
with no significant difference between the two groups on each day of measurement.  
Week 0 was the injection week and the mice diet was switched to AIN-93G regular diet 
or genistein diet and maintained throughout the study until the mice were sacrificed after 
3 weeks.   
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Figure IV-2: Uterine wet weight of sample groups during necropsy 
 
Results were expressed as mean ± standard error.  Control group with n = 16 while 
genistein group with n = 14.  There was no statistical difference in the average uterine 
wet weights measured between the genistein group (9.89 ± 1.0 mg) and the control 
group (9.86 ± 0.9 mg).   
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 Control Genistein 
Day 2 0 / 5 (0%)  0 / 5 (0%) 
Day 6 1 / 7 (14.29%) 1 / 6 (16.67%) 
Day 9 4 / 16 (25.00%) 3 / 15 (20.00%) 
Day 13 13 / 16 (81.25%) 12 / 15 (80.00%) 
Day 16 14 / 16 (87.50%) 11 / 15 (73.33%) 
Day 21  14 / 16 (87.50%) 10 / 14 (71.43%) 
 
Table IV-1: Metastasis occurrence rate of sample groups over test period 
 
Results were expressed as the number of metastasis occurrences over the sample size 
with the percentage occurrence calculated in blankets.  On Day 2 and 6, half of the 
entire population of the two groups was imaged for metastasis.  While on Day 9, 13, 16 
and 21, all the mice were undergoing BLI and one mouse was found dead in the 
genistein group on Day 21.  The rate increased rapidly from Day 9 to Day 13 and stayed 
high towards the end of the study with the control group showing relatively higher 
number and percentage of metastasis.   
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Day 2                        Day 6                       Day 9 
 
       
Day 13                      Day 16                      Day 21 
 
Figure IV-3: Metastasis progression over time in control mouse number 11 
 
The bioluminescence images were taken from Day 2 to Day 21.  For Day 2, Day 6 and 
Day 9, there was no visual metastasis from BLI.  The metastasis was first detected on 
Day 13.  It kept spreading and the light emitted from the enzymatic reaction captured by 
the camera became increasingly stronger until saturation at the end of the study.   
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Figure IV-4: Different locations of metastasis other than lungs in test mice 
 
Other organs including the lymph node (control mouse #19), abdomen (genistein mouse 
#32), leg (control mouse #3) and pelvis (genistein mouse #16) had shown metastasis 
on the bioluminescence images.  Those metastases were also measured and counted 
as the overall metastasis in the animals.   
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Figure IV-5: BLI area results of two diet groups over time 
 
Results were expressed as mean ± standard error.  Control group had n = 16 while 
genistein group had n = 14/15.  No sign of metastasis for the first 2 days of imaging.  
Trend of increasing metastasis from Day 9 to Day 21 observed for both groups with the 
control group showing more metastasis on each day of measurement and its level 
increased more rapidly than that of the genistein group.  No significant difference in 
metastasis area between the two groups.   
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Figure IV-6: BLI integrated density results of two diet groups over time 
 
Results were expressed as mean ± standard error.  Control group had n = 16 while 
genistein group had n = 14/15.  It showed similar trend with the result of the BLI area.  
Similarly, the integrated density of the control group was not significantly different than 
that of the genistein group.   
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Original lung sample before staining 
       
India ink-infused lung sample 
 
Figure IV-7: Appearance of original and India ink-infused lung sample specimens 
 
India ink infusion resulted in white tumor nodules on the black background of India ink-
infused normal lung tissue.  It enhanced the visual counting of the tumor burden on the 
lungs and it also increased the volume of the lung and hardened the lung tissue for 
easier dissection in the following H and E staining.   
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Figure IV-8: Tumor count on lung surface of sample groups 
 
After India ink staining, white tumor nodules on the lung samples were counted 
independently by 3 individuals who were blind to the study design.  Results were 
expressed as mean ± standard error.  Control group with n = 16 and genistein group 
with n = 14.  On average, 2.15 ± 0.57 tumors were counted on the lung surface of the 
control group compared to 1.95 ± 0.49 tumors in the genistein group.  The genistein diet 
administrated after cancer cell injection showed no significant effect on the tumor 
burden observed in the animal model compared to that of the control group.   
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Figure IV-9: Macro-metastasis of sample lung tissue observed after H and E staining 
 
Large tumor areas stained with H and E on the black background of the India ink-
stained normal lung tissue.  Each area was counted as one tumor colony and its area 
was measured.   
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Figure IV-10: Micro-metastasis of sample lung tissue observed after H and E staining 
 
Arrows indicate much smaller tumor areas within the lung tissue compared to the 
macro-metastasis.  Each area was counted as one tumor colony and its area was 
measured.   
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Figure IV-11: Tumor count of sample groups observed after H and E staining 
 
Both macro- and micro-metastasis were counted and added together for each slide of 
lung tissues and average was taken from all the animal samples for each group.  
Control group with n = 16 and genistein group with n = 14.  Results were expressed as 
mean ± SEM.  On average, control group had 4.31 ± 1.14 tumor colonies on the lung 
tissue compared to 4.20 ± 0.99 tumor colonies from the genistein group.  Although the 
control group showed slightly more tumor colonies than that of the genistein group, 
there is no significant difference in the number of tumor developed between the two 
groups.  The results were similar to those of the India ink tumor counting.   
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Figure IV-12: Tumor to lung area ratio of sample groups observed after H and E staining 
 
Control group with n = 16 while genistein group with n = 14.  For each of the lung 
samples, both the tumor area and the whole lung area on the slide were measured and 
the results were expressed as:  
                
Control group showed lower tumor area/lung area ratios and its average ratio was also 
smaller than that of the genistein group but the differences were not statistically 
significant when analyzed using the Wilcoxon Rank Sum Test.   
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CHAPTER V     DISCUSSION 
BC is the most commonly diagnosed and the second most common cause of cancer 
death among women after lung cancer in the US.  BC causes more than 40,000 deaths 
in women each year, the majority of which are due to metastasis to distant organs122.  
As a result, cancer researchers have begun to pay more attention to the mechanisms of 
metastasis and the potential therapies targeting this process.   
 
It is extremely difficult to treat the disease once cancer has metastasized and our 
results of BLI images also showed that once the metastasis was detected by BLI, it kept 
spreading and the light captured from the tumor became increasingly stronger (Figure 
IV-3).  Hence, treatments that influence the development of metastasis may potentially 
affect overall BC survival.   
 
BC rates increase with age and ~75% of cancer cases occur in women age 50 or older 1 
and ~70% are estrogen-dependent123.  Because of the significantly reduced ovarian 
function of postmenopausal women, the estrogen levels in their body reduce drastically. 
During menopause, the ovaries stop producing estrogen.  Circulating estrogen levels in 
postmenopausal women range from 20–150 pM124 , which is much lower than the 
estrogen levels observed in pre-menopausal women (700-3500 pM at pre-ovulation) 125.   
Since estrogens are essential for normal functions of the female reproductive system, 
such as breast development and menstrual cycle, the decreased hormonal levels result 
in a variety of symptoms, including vasomotor symptoms (hot flashes and night sweats), 
vaginal symptoms (dryness, discomfort, itching and dyspareunia) and neurological 
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symptoms (trouble sleeping, depression, anxiety, memory loss and headache).  One of 
the harsh consequences of low estrogens is severe osteoporosis.  That is one of the 
main reasons why HRT became popular to replace the failing estrogen levels in the 
body in order to relieve these symptoms traditionally.   
 
However, connection between estrogen and BC was first recognized in 1896 when a 
Scottish doctor George Beatson showed regression of mammary tumors with 
ovariectomy of pre-menopausal women with advanced BC 126 .  More recent 
epidemiologic data observe higher BC risk in women with prolonged period of estrogen 
exposure127.  Elevated serum and urine estrogen concentrations have been observed in 
postmenopausal BC patients 128 , 129 .  All these observations suggest excessive 
endogenous hormones, especially estrogens, may increase the chance of developing 
BC.  In addition, exogenous hormone use can raise circulating estrogen levels in the 
body and affect BC risk as well. Both HRT 130,131 and oral contraceptives 132 have been 
reported to increase the risk of the disease.  Women’s Health Initiative, a large 
randomized clinical trial, reported that a 5-year treatment of estrogen plus progestin 
increased the risk of BC and heart disease in healthy postmenopausal women2.   
Furthermore, study has shown that ER+ BC incidence decreased following the drop of 
HRT use that began in 2002 133  and the decrease is particularly significant among 
women aged 50-69 years, in whom HRT use is the most common.  All these evidences 
indicate that estrogen plays an important role in the growth and development of BC, 
especially in postmenopausal women.   
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As a result, many oncologists do not recommend HRT to BC patients due to the 
concern that it may also increase the risk of metastatic BC.  Therefore, in the US, more 
and more of these women tend to self-medicate with dietary supplements containing 
soy isoflavones as an alternative therapy to relieve menopausal symptoms and improve 
bone health.  Approximately 30% of Americans are using at least one complementary 
and alternative medicine (CAM) such as dietary and herbal supplements per year, 
typically for chronic rather than acute medical conditions134.  In addition, a recent review 
showed that 45% of BC patients used CAM (including soy isoflavones) not prescribed 
by physicians 135 , 136 .  In the last decade, phytoestrogen-containing products have 
increased in the market about 4-fold137.   
 
Soy isoflavones are assumed to be a safe alternative to HRT with the perception that 
these phytoestrogens are without the risks associated with HRT since they are from 
natural products and soy has been proven to have many health benefits based on some 
epidemiologic studies.  However, consumption of whole soy foods may have different 
effects than that of isolated soy isoflavones and hence isoflavones, in pure form, as in 
supplements, may pose some health concerns to metastatic BC patients.   
 
The role that isoflavones play in BC is unclear.  Genistein, being the major isoflavone in 
soybeans, acts as an estrogen agonist at physiologically relevant dosages138.  Some 
reports indicate that genistein can prevent the development of BC.  Studies published 
over the last 5 years have demonstrated that exposure to dietary genistein before 
puberty reduces the number of chemically induced mammary tumors formed in female 
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Sprague Dawley rats.  Whereas others show that genistein stimulates the growth of 
existing estrogen-dependent tumors.   
 
The objective of the current study was to evaluate the effect of dietary genistein, being 
the most abundant and active component in soybeans, on BC metastasis using 4T1 
inoculated OVX BALB/c mouse model which mimics postmenopausal women with 
metastatic BC.  This research is important because genistein exists in high 
concentration in isoflavone-containing foods or supplements that may be consumed by 
many women including BC survivors for alleviating menopausal symptoms.  Our animal 
model injected with 4T1 cell line is a syngeneic model which mimics postmenopausal 
women with a highly metastatic BC and genistein was administrated after cancer onset.  
Hence, the results from this study assist in the investigation of the effects of genistein 
on BC metastasis and the safety concerns of consuming dietary isoflavone supplements 
by BC patients to treat menopausal symptoms.   
 
There are several reasons of using 4T1 cancer cell: 1) it is a murine cell line originated 
from a single mouse mammary tumor by Miller in 1983139,140, which is from the same 
species of the experimental animals.  This can eliminate the use of immuno-
compromised nude mice if human cells are used which may not be an ideal model to 
study metastasis when considering the interaction between tumor cells and the host 
animal; 2) it can develop spontaneous metastasis in a similar manner to that observed 
in a clinical environment; 3) the luciferase genes stably integrated 141  allow the 
quantification of 4T1 cells in vivo using BLI, which is a fast, convenient, sensitive and 
 55 
 
non-invasive method of detecting and monitoring the spread and severity of tumor 
metastases in real-time.  Previously, our team conducted an in vitro assay to evaluate 
the luciferase activity of 4T1 cells.  The intensity of light from BLI was positively 
correlated with the number of 4T1 cells, indicating that it is an effective technique to 
monitor tumor growth.   
 
The conventional tail vein injection approach we used can directly introduce cancer cells 
into the blood circulation of the animals and easily induce metastasis in organs that 
have a rich blood supply, such as lungs.  We observed majority of lung metastasis from 
BLI together with few other metastatic locations (Figure IV-4) including lymph nodes, 
abdomen, legs and pelvis.  However, one of its potential disadvantages is that there is 
no primary tumor established.  Cancer metastasis usually involves the establishment of 
primary tumor, infiltration of tumor cells into the circulation and development of distal 
metastasis.  Elimination of early steps in metastasis cascade may change the 
interpretation of the results.  In some cases, lung metastasis developed from tail vein 
injection has been described as multiple primary tumors in the lungs because of the 
absence of primary tumors.  Also, after tail vein injection, most of the tumor cells would 
be killed by the immune system, which caused a long latent period.  Other metastasis 
models can be considered, such as the injection of cancer cells to mammary fat pad or 
bone marrow cavity of tibia.  Mammary fat pad injection is more similar to human BC 
and includes all the necessary steps of disease progression but the fast growth of 
primary tumor will be problematic.  With enriched blood supply and growth factors, bone 
is the most common site for BC metastasis.  In addition, due to the development of 
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primary bone metastasis in the intra-tibia injection model, the development of lung 
tumors can be considered as secondary metastasis.  Hence, in our future studies, we 
may consider using different injection models to elucidate the mechanism of different 
metastasis patterns caused by various injection routes and determine if the use of 
different cell administration routes would affect BC metastasis and the outcomes of 
different dietary treatments.   
 
Since different concentration of isoflavones applied will alter their hormonal effects as 
discussed previously, it is important to focus on their effects at plasma concentrations 
that are relevant to what is observed in humans consuming isoflavone-containing diets.  
In our animal study, 750ppm of dietary genistein dosage had been chosen to evaluate 
its effect on BC metastasis.  Based on our previous studies, this dosage provides 
approximately 1 to 2 µM plasma genistein concentration in mice, which is similar to the 
blood levels in women consuming soy supplement in the US 142 and women consuming 
varying amounts of isoflavones from soy milk143.   
 
Once the two different dietary treatments (control and genistein) began, BLI was 
performed to detect metastasis and monitor tumorigenesis in which the metastasis 
occurrence rate and area could be recorded throughout the study (Table IV-1 and 
Figure IV-5).  At the end of the study after sacrificing the animals, the metastatic tumor 
burden on the lungs was counted with India ink staining and macro- as well as micro-
metastases were detected using H and E staining of the lung samples from both the 
genistein treated animals and control animals.   
 57 
 
All of the data collected could give an overall view of the seriousness and extent of BC 
spread in the experimental animals due to the genistein diet.  In general, mice in 
genistein diet group exhibited less lung metastasis than those in control group.  The 
lungs from genistein treated mice showed less tumor nodules and smaller tumor areas 
(both macro-metastasis and micro-metastasis) than that of the control animals.  
However, the differences were not statistically significant and we can conclude that 
genistein has no estrogenic effect on breast caner metastasis in this study.   
 
Also, when observing the uterine wet weight of the two groups, there was no detectable 
uterotrophic effect by genistein as well.  It may be due to the fact that genistein is only a 
weak estrogen agonist, which has a much lower affinity to ERs than that of estradiol and 
hence its estrogenic effect on uterus is much weaker.  Also, since ER-α is dominant in 
breast and uterus and ER-β is preferentially expressed in heart, prostate and bone144,  
genistein, being shown to have a much higher affinity to ER-β than ER-α and an affinity 
to ER-α 100-1000 times lower than estrogen, is believed to pose less estrogenic effect 
on uterus.  This may be beneficial in reducing the risk of endometrial cancer when 
consuming genistein.   
 
Most of our previous studies were designed to evaluate the effect of soy isoflavones, 
being weak estrogens, on ER+ BC and the related treatments on their growth.  However, 
in this study, 4T1 cells were chosen to represent the later stage BC cells.  4T1 cells are 
estrogen non-responsive and ER-α negative.  Hence, the effect on lung metastasis by 
genistein was more likely to be indirect.  Two recent studies have demonstrated that 
 58 
 
estrogen promoted metastasis by influencing the host physiology and they suggested 
that estrogenic compounds may also affect metastasis indirectly145,146.  Since genistein 
is estrogenic and acts similar to estrogen, it is possible that genistein exerts similar 
systemic effects on the microenvironment for tumor to metastasize.  Additionally, 
isoflavones have also been found to have non-hormonal activities independent of the 
ER147.  It has been suggested that soy isoflavones may influence BC risk via their anti-
proliferative, anti-angiogenic, anti-oxidative and anti-inflammatory properties 148 .  
Nevertheless, the specific actions of genistein on this process are still unclear.  
Although this study showed no effect of genistein influencing the overall tumor 
progression and tumor burden appeared on lungs, other possible mechanisms may 
involve angiogenesis, growth factors or other steps during the metastatic process.   
 
Isoflavones possess diverse biological activities and potencies.  These activities are 
often dependent upon the concentration and timing of administration of the isoflavones 
and the types of cancer cells.  In regard to BC, isoflavones, specifically genistein, have 
paradoxical effects.  For example, genistein has a stimulatory effect at lower 
concentrations and an inhibitory effect at higher concentrations and only minor changes 
in dose can dramatically alter its biological responses149.  Also, pre-pubertal exposure to 
genistein appears to be protective against the development of BC, but consumption of 
the phytoestrogen in either pure form or in soy protein isolate after the development of 
an estrogen-dependent BC may enhance tumor growth, while our study demonstrates 
that dietary genistein has no beneficial or adverse effect on lung metastasis of estrogen 
non-responsive BC in vivo.   
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Consumption of soy isoflavones as dietary supplements may have numerous health 
benefits such as reducing risk of cardiovascular disease, osteoporosis and alleviating 
menopausal symptoms but the biological activities of genistein may be different once a 
cancer exists150.  As a result, additional investigation into the biological activities and 
specific actions of genistein including effects on estrogen metabolizing enzymes, cell 
cycle, cell differentiation, proliferation, apoptosis, the inflammatory response and 
various other cell signaling pathways and the mechanisms involved in metastasis is 
needed in order to fully evaluate the biological relevance of experimental findings and to 
conclude if the consumption of genistein-containing products will be advisable and have 
no adverse effect on BC progression for the subgroup of postmenopausal women who 
have or are at high risk of developing BC.  
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CHAPTER VI    CONCLUSIONS AND FUTURE DIRECTIONS 
 
A. Conclusions 
Soy isoflavones have functional similarity to human estrogens and may protect against 
BC as a result of their anti-proliferative activity or increase risk as a result of their 
estrogen-like properties.  Hence, in the current study, we examined the relationship 
between isoflavones supplementation and BC metastasis, the major cause of BC 
deaths among postmenopausal women.  Since distant metastasis is associated with 
increased mortality, BC patients need to be cautious when consuming products 
containing phytoestrogens such as genistein for the treatment of menopausal symptoms.   
 
The specific objective of the study presented in this thesis was to evaluate the effect of 
dietary genistein on BC metastasis using preclinical animal models implanted with 4T1 
murine BC cells via 1) the application of BLI techniques to monitor tumor progression; 2) 
the use of India ink staining to estimate the metastatic tumor burden on the lung surface; 
3) the analysis of H and E stained lung samples of micro-metastases.   
 
BLI has proved to be a very effective technique for monitoring metastasis progression in 
vivo and real-time semi-quantitative data could be collected without sacrificing the 
animals throughout the experimental period.  From the BLI data, we found that genistein 
diet did affect the metastasis occurrence rate during the study.  There was no effect on 
BLI areas and integrated density of the metastasis areas with genistein supplementation.   
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Secondly, with the enhanced visual counting of the India ink-infused lungs, 750ppm of 
dietary genistein was found to have no significant effect on 4T1 tumor growth on the 
lungs.   
 
The last experiment was designed to detect and count the micro-metastasis in mice on 
the two diet treatments.  The impact of dietary genistein on the total lung metastasis 
count was not significant and the tumor area measured was not different for the 
genistein group from the control group.  To conclude, there is no significant difference in 
tumor burden in the lung tissues between the two diet groups.   
 
In summary, although we did not observe a beneficial effect of soy-derived isoflavones 
on BC metastasis, there was also no sign of adverse effects.  Hence, from this study we 
can conclude that dietary genistein has no effect on BC metastasis and lung tumor 
burden in postmenopausal animal model when supplemented after cancer cell 
implantation.   
 
It can be concluded that although genistein has an estrogen-like structure but it may not 
have a strong systemic effect as the endogenous estrogens on the microenvironment 
that is important for metastatic tumor development.  However, on the other hand, 
genistein may act on the other pathways or mechanisms involved in metastasis for it is 
a complex and multi-factor disease.  As a result, further BC metastasis research is 
needed to produce more consistent preclinical data in order to determine if the 
consumption of genistein is safe for BC survivors, especially for women in their 
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postmenopausal age group, for genistein is hypothesized to exert greater estrogenic 
effects in a low endogenous estrogen environment151.  Future investigation of the effect 
of dietary genistein on BC metastasis and the understanding of the related mechanisms 
is important to help health professionals to make appropriate recommendations on 
isoflavones supplement consumption.   
 
B. Future directions 
Evaluation of metastatic occurrence and lung tumor burden is one way of representing 
BC metastatic stage.  It is necessary to conduct more research to investigate the 
possible mechanisms or pathways on how isoflavones act to influence BC metastasis 
through the systemic effects on metastatic tumor development.  The future directions of 
the research may include:  
 
1) To evaluate the effects of dietary genistein on different possible cellular mechanism 
of BC metastasis including the regulation of cell cycle (proliferation) and programmed 
cell death (apoptosis).  The ratio between proliferation and apoptosis regulates 
metastatic tumor growth and expansion of metastases.  Some studies had 
demonstrated that dietary genistein significantly decreased the percentage of 
proliferating tumor cells and significantly increased apoptotic tumor cells;  
 
2) To evaluate the effects of dietary genistein on BC metastasis when it is taken before 
cancer cell injection to investigate if it can act as a preventive measure to BC for 
postmenopausal women and if it will show more significant protective results since all of 
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the results in this study were not significant although genistein had shown to have 
lowered metastases and lung tumor burden compared to control.  Hence, it is suspected 
that genistein may show more significant beneficial effects if taken before BCs exist in 
the body;  
 
3) To vary other factors, for examples dosage of genistein, timing of administration and 
form or level of processing, to investigate the difference in effects on BC metastasis;  
 
4) To evaluate the effects of dietary genistein on metastasis to other tissues using 
different administrative routes such as the mammary fat pad injection model or intra-
tibia injection model for there may be some drawbacks of the tail vein injection model;  
 
5) To evaluate other isoflavones compounds such as daidzein and equol and their 
effects on BC metastasis.   
 
Some of these proposed studies are under investigations by the colleagues in our 
laboratory and we are looking forward to reporting our research findings in the near 
future.   
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